

5/21/98

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 1998 ACS
AN 1997:23872 CAPLUS
DN 126:73609
TI Expressions of heat shock proteins under heat-stress and
interferon-treatment: An in vitro study on osteosarcoma
AU Kubo, Toshikazu; Tamura, Yuji; Takahashi, Kenji; Imanishi, Jiro;
Hirasawa, Yasusuke
CS Department Orthopaedic Surgery, Kyoto Prefectural University
Medicine, Kamigyo, 602, Japan
SO Pathophysiology (1996), 3(4), 233-239
CODEN: PTHOE7; ISSN: 0928-4680
FB Elsevier
DT Journal
LA English
AB This study examd. expressions of heat shock proteins (HSP) under
heat-stress and/or interferon (IFN)-.alpha., .beta., or .gamma.
treatment using a human osteosarcoma cell line, NY cells. IFN alone
as well as heat-stress at 43-45.degree. for 60 min suppressed cell
growth, and their combination resulted in synergistic suppression.
When primary heat stress was given, cells acquired thermotolerance
at the second heat-stress. Autoradiog. revealed that HSP70 was
mainly induced in the cells under heat-stress. In Western blot
anal., heat (44.degree.)-induced HSP70 was suppressed by IFN
treatment. This suggests that synergistic suppression effects of
the combination treatment on osteosarcoma cells would be
attributable to the suppression of HSP70 expressions. Optimum
combination of heat-stress and IFN is expected to increase the cure
rate in osteosarcoma treatment.
IT Interferon .alpha.
Interferon .beta.
Interferon .gamma..
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(heat shock proteins expression under heat-stress and
interferon treatment of osteosarcoma)

L7 ANSWER 2 OF 2 USPATFULL
AN 95:45355 USPATFULL
TI Controlled release of drugs or hormones in biodegradable polymer
microspheres
IN Modi, Pankaj, 1298 Main St. W., Apt. 608, Hamilton, Ontario,
Canada L8S 1J4
PI US 5417982 950523
AI US 94-197756 940217 (8)
DT Utility
EXNAM Primary Examiner: Griffin, Ronald W.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A controlled release formulation for use with a variety of drugs
or hormones are formed in microspherical form. The drug or
hormone, e.g. bovine somatotropine, is suspended in a polymer
matrix. The polymer matrix is formed from at least two highly
water soluble biodegradable polymers, selected for example from
starch, crosslinked starch, ficoll, polysucrose, polyvinyl
alcohol, gelatine, hydroxymethyl cellulose, hydroxyethyl